ERBB2 and breast cancer: For patients with detected ctDNA after NAT, all twelve Her2-positive breast cancer patients received postmastectomy adjuvant anti-Her2 therapy; one received trastuzumab emtansine, another received trastuzumab plus pertuzumab, and the remaining patients received trastuzumab for one year.